ArticleAmerican journal of translational research2025
Development of a carbon nanoparticle-guided nomogram for predicting lateral cervical lymph node metastasis in clinically node-negative papillary thyroid carcinoma.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop and validate a carbon nanoparticle-enhanced nomogram for predicting lateral lymph node (LLN) metastasis in patients with clinically node-negative (cN0) papillary thyroid carcinoma (PTC).
methodsA retrospective analysis was conducted on 421 cN0 PTC patients treated between 2014 and 2020. Patients were randomly divided into training (n=316) and internal validation (n=105) cohorts. Least absolute shrinkage and selection operator (LASSO) regression and Cox regression analyses were performed to identify predictive factors from clinical, ultrasonographic, and carbon nanoparticle tracing data. Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA).
resultsIndependent predictors identified included age (HR: 0.944, 95% CI: 0.908-0.982), tumor diameter ≥1 cm (HR: 0.221, 95% CI: 0.053-1.920), regular tumor morphology (HR: 0.090, 95% CI: 0.020-0.470), and the number of carbon nanoparticle-stained positive lateral lymph nodes (HR: 0.000, 95% CI: 0.000-0.231). The nomogram showed excellent discrimination, with an AUC of 0.911 in the training set and 0.916 in the validation set, and good calibration (Brier scores of 5.70 and 4.50, respectively). DCA confirmed the clinical utility of the model across a range of risk thresholds.
conclusionThis carbon nanoparticle-guided nomogram is a practical and highly accurate tool for intraoperative risk stratification of LLN metastasis in cN0 PTC patients. Integrating tracer-based lymph node assessment with conventional clinicopathological factors enhances predictive capability compared to existing methods, potentially reducing unnecessary neck dissections while ensuring appropriate management of high-risk cases. Multicenter validation and incorporation of molecular markers are important next steps toward clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.